Active versus expectant management for premature rupture of membranes at term: A randomized, controlled study
Fredrick I. Awkadigwe, Frank O. Ezugwu, George U. Eleje, Sylvester O. Nweze, Boniface U. Odugu, Victor O. Dinwoke, Ephraim A. Olu, Kelvin E. Ortuanya, Malachy N. Ezenwaeze, Obiechina C. Eze, Johnson I. Onyekpa, Ifeanyichukwu J. Ofor, Osmond O. Onah, Chimdalu U. Omeje, Andre U. Ezike, Perpetua K. Enyinna, Divinefavour E. Malachy, Chigozie G. Okafor- Biochemistry (medical)
- Cell Biology
- Biochemistry
- General Medicine
Objective
To compare the effects on feto-maternal outcomes of expectant versus active management for premature rupture of membranes (PROM) at term.
Methods
This was a prospective randomized (1:1) controlled study involving 86 pregnant-women who received either expectant management (n = 43) or active management with misoprostol (n = 43) for PROM at term. Primary outcome was route of delivery. Secondary outcomes were: PROM to presentation interval; latency period; PROM to delivery interval; recruitment to delivery interval; labour and delivery complications.
Results
Baseline-characteristics were similar between groups. There was no significant difference between active and expectant groups in mean PROM to presentation/admission, or PROM to delivery. However, mean latency period (11.1 ± 7.3 hours vs 8.8 ± 5.5 hours) and mean recruitment to delivery intervals after PROM (14.7 ± 5.2 hours vs 11.8 ± 5.0 hours) were significantly shorter for the active group compared with the expectant group. Although the rate of caesarean section was less in expectant management group (21%) compared with the active management group (30%), the difference was not statistically significant. There were no significant differences between groups in delivery or perinatal complications.
Conclusion
Active and expectant management for PROM at term gave comparable outcomes in terms of methods of delivery and complications. However, active management significantly shortened the latency period and induction to delivery intervals compared with expectant management. Trial-Registration: Pan-African-trial-registry-(PACTR)-approval-number PACTR202206797734088